PLEXUS CORP — Director's Dealing 2023

Jan 31, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PLEXUS CORP (PLXS)
CIK: 0000785786
Period of Report: 2023-01-27

Reporting Person: Darroch Ronnie (EVP Global Ops & Reg Pres-EMEA)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-27	Common Stock, $.01 par value	M	5320	—	Acquired	5320	Direct
2023-01-27	Common Stock, $.01 par value	F	2554	$93.56	Disposed	2766	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-27	Restricted Stock Units	$	M	5320	Disposed		Common Stock (5320)	Direct
2023-01-30	Restricted Stock Units	$	A	3900	Acquired		Common Stock (3900)	Direct
2023-01-30	Performance Stock Units	$	A	3590	Acquired		Common Stock (3590)	Direct

Footnotes

F1: Each Restricted Stock Unit granted under the Plexus Corp. 2016 Omnibus Incentive Plan, which qualifies under Rule 16b-3, represented a contingent right to receive one share of Plexus Corp. common stock. The Restricted Stock Units vested and settled on January 27, 2023.

F2: Each Restricted Stock Unit granted under the Plexus Corp. 2016 Omnibus Incentive Plan, which qualifies under Rule 16b-3, represents a contingent right to receive one share of Plexus Corp. common stock. The Restricted Stock Units vest on January 30, 2026.

F3: Each Performance Stock Unit ("PSU") granted under the Plexus Corp. 2016 Omnibus Incentive Plan, which qualifies under Rule 16b-3, represents a contingent right to receive one share of Plexus Corp. common stock if certain conditions are satisfied. Vesting of 1,640 PSUs is dependent on the relative total shareholder return ("TSR") of Plexus Corp.'s common stock as compared to companies in the S&P 400 Index and vesting of the remainder is based on goals related to economic return ("ER") during the three-year performance period. The target number of PSUs that may be earned is reported above. The reporting person may earn up to 150% of the targeted amount that is based on TSR and up to 200% of the targeted amount that is based on ER.